CJC-1295 vs ACE-031
Side-by-Side Comparison
| Attribute | Cjc 1295 | Ace 031 |
|---|---|---|
| Category | Growth Hormone Secretagogue | Muscle Growth / Research |
| Mechanism | CJC-1295 binds to GHRH receptors (GHRHR) on pituitary somatotroph cells, activating intracellular cAMP signaling to stimulate both the transcription of the GH gene and pulsatile release of endogenous... | ACE-031 is a decoy receptor — it mimics the natural ActRIIB receptor and binds myostatin, activin A/B, GDF-11, and BMP-9/10 before they can engage cell-surface receptors. |
| Evidence Rating | D — Preclinical | C — Early Human or Mixed Evidence |
| Clinical Status | Research-only / Not approved for human use | Phase I/II completed (DMD). Development discontinued by Acceleron Pharma (2013) due to vascular adverse events. Successor programs (ACE-083, local) also discontinued. |
| Safety Profile | Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief; Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) | CRITICAL: Vascular safety signals led to clinical discontinuation; Epistaxis (nosebleeds) in multiple subjects |
| Route | Subcutaneous | Subcutaneous injection (DISCONTINUED CLINICAL PROGRAM) |
| Dose Range | No DAC: 100 mcg before bed daily; DAC: 1–2 mg 2–3x weekly | 0.5-3 mg/kg every 2 weeks (clinical trial doses) |
| Frequency | Once daily (no DAC) or 2–3 times weekly (with DAC) | Once every 2 weeks (from clinical trial protocol) |
| Molecular Weight | No DAC: ~3367.9 g/mol; With DAC: ~3647.3 g/mol | ~90,000 g/mol (Fc-fusion protein) |
| Half-Life | No DAC (mod GRF 1-29): ~30 min; With DAC: ~8 days | ~10-14 days (Fc-mediated FcRn recycling) |
Overview
CJC-1295 and ACE-031 are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
CJC-1295 — Mechanism & Evidence
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) originally developed by ConjuChem Technologies for HIV-associated lipodystrophy. It exists in two forms: with DAC (Drug Affinity Complex) for extended half-life of 5.8-8.1 days, and without DAC (Mod GRF 1-29) for shorter, pulsatile release with a half-life of approximately 30 minutes. Two 2006 randomized, placebo-controlled, double-blind clinical trials (Teichman et al.) demonstrated dose-dependent GH increases of 2-10 fold and IGF-1 increases of 1.5-3 fold in healthy adults aged 21-61. The No DAC version is generally considered the safer choice due to its physiological pulsatile pattern.
Key claims: Increases growth hormone and IGF-1; Improves body composition; Promotes deep sleep.
ACE-031 — Mechanism & Evidence
ACE-031 is a soluble form of the activin type IIB receptor (ActRIIB) fused to a human IgG1 Fc domain (MW ~90,000 g/mol). It functions as a ligand trap, sequestering myostatin, activin, GDF-11, and other TGF-beta superfamily members that signal through ActRIIB to suppress muscle growth. Acceleron Pharma conducted Phase I and Phase II clinical trials in Duchenne muscular dystrophy (DMD) before discontinuing development due to vascular safety signals (nosebleeds, telangiectasias).
Key claims: Increases lean muscle mass; Potential therapy for muscular dystrophy; Broadly inhibits muscle-wasting pathways.
Shared Research Applications
Both peptides are studied for: Body Composition.
CJC-1295 is also researched for: Anti-Aging.
ACE-031 is also researched for: no additional unique applications.
Safety Considerations
CJC-1295: Common: transient flushing/"head rush" within 5-10 minutes post-injection — hallmark of a potent injection, harmless and brief Self-reported: flu-like symptoms, headaches, irritability, anxiety, nausea, hives (mild and transient) Water retention and edema (dose-dependent; elevated GH causes sodium/water retention via kidneys)
ACE-031: CRITICAL: Vascular safety signals led to clinical discontinuation Epistaxis (nosebleeds) in multiple subjects Telangiectasias (dilated blood vessels in skin/mucosa)
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
CJC-1295 + Ipamorelin: Growth Hormone Stack Mechanics
CJC-1295 and Ipamorelin form the most studied growth hormone peptide combination in research. They target separate receptor pathways to boost GH secretion through the somatotropic axis. This stack produces amplified GH pulses, with preclinical data showing 3 to 5 times baseline levels versus 1.5 to 2 times alone.
Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release
Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.